Health
HPV vaccine gains FDA approval
NEWS IN BRIEF — Posted June 26, 2006
The Food and Drug Administration approved on June 8 the first vaccine to prevent cervical cancer, precancerous genital lesions and genital warts caused by the human papillomavirus, types 6, 11, 16 and 18. It was approved for girls and women ages 9 to 26.
The vaccine, Gardasil, manufactured by Merck & Co., was evaluated and approved in six months via the FDA's priority review process.
Gardasil is a recombinant vaccine given as three injections over a six-month period. It will not eliminate the need for routine Pap screening, as women are not protected if they had been infected with the virus prior to receiving the shot. Also, while it protects against the HPV strains that most commonly lead to disease, it doesn't protect against all types.
Merck tested the safety of the vaccine in about 11,000 people. The most common adverse effects included mild moderate local reaction including pain or tenderness at the site of the injections.
Merck reported five congenital anomalies in babies born to women who conceived within 30 days of receiving the vaccine, prompting monitoring of women who received Gardasil while unknowingly pregnant.
There is also an ongoing study to evaluate the safety and effectiveness of the vaccine in males.
Note: This item originally appeared at http://www.ama-assn.org/amednews/2006/06/26/hlbf0626.htm.












